-+ 0.00%
-+ 0.00%
-+ 0.00%

According to EY's latest white paper, the top 25 global biopharmaceutical companies are expected to face a potential business growth gap of 100 billion US dollars by 2028, and the gap will exceed 370 billion US dollars by 2032.

Zhitongcaijing·07/22/2026 11:25:04
Listen to the news
According to EY's latest white paper, the top 25 global biopharmaceutical companies are expected to face a potential business growth gap of 100 billion US dollars by 2028, and the gap will exceed 370 billion US dollars by 2032.